KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Tax Provisions: 2011-2025

Historic Tax Provisions for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Sep 2025 value amounting to -$12.8 million.

  • Supernus Pharmaceuticals' Tax Provisions fell 299.15% to -$12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 113.00%. This contributed to the annual value of $24.0 million for FY2024, which is 1552.10% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Tax Provisions stood at -$12.8 million, which was down 120.19% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Tax Provisions registered a high of $25.9 million during Q3 2023, and its lowest value of -$16.3 million during Q2 2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Tax Provisions value was $119,000 (recorded in 2024), while the average stood at $1.2 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first slumped by 565.71% in 2023, then skyrocketed by 6,048.65% in 2024.
  • Supernus Pharmaceuticals' Tax Provisions (Quarterly) stood at -$391,000 in 2021, then spiked by 2,570.33% to $9.7 million in 2022, then crashed by 101.92% to -$185,000 in 2023, then spiked by 6,048.65% to $11.0 million in 2024, then tumbled by 299.15% to -$12.8 million in 2025.
  • Its Tax Provisions was -$12.8 million in Q3 2025, compared to -$5.8 million in Q2 2025 and $6.0 million in Q1 2025.